Suscribirse

Dectin-1 activation unlocks IL12A expression and reveals the TH1 potency of neonatal dendritic cells - 06/11/15

Doi : 10.1016/j.jaci.2015.02.030 
Sébastien Lemoine, PhD a, b, Barbara Jaron, PhD a, b, Sabrine Tabka, MSc a, b, Chourouk Ettreiki, PhD c, i, Edith Deriaud, BSc a, b, Dania Zhivaki, MSc a, b, d, Camille Le Ray, MD e, f, Odile Launay, MD, PhD f, g, Laleh Majlessi, PhD h, Pierre Tissieres, MD, PhD c, i, j, Claude Leclerc, PhD a, b, Richard Lo-Man, PhD a, b,
a Unité de Régulation Immunitaire et Vaccinologie, Institut Pasteur, Paris, France 
b INSERM U1041, Paris, France 
c Unité de Réanimation Pédiatrique et Médecine Néonatale, AP-HP, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France 
d Université Paris Diderot, Paris, France 
e APHP, Department of Obstetrics and Gynecology, Maternité Port Royal, Paris, France 
f Université Paris Descartes, Faculté de Médecine, Paris, France 
g INSERM CIC1417, Paris, France 
h Unité de Pathogénomique Mycobactérienne Intégrée, Institut Pasteur, Paris, France 
i Groupe Equipe Endotoxine, Structures et Activité, Institut de Génétique et Microbiologie, UMR 8621, Université Paris Sud, Orsay, France 
j Faculté de Médecine, Université Paris Sud, Le Kremlin Bicêtre, France 

Corresponding author: Richard Lo-Man, PhD, Régulation Immunitaire et Vaccinologie, 25 rue du Docteur Roux, Institut Pasteur, Paris, France.

Abstract

Background

Early life is characterized by a high susceptibility to infection and a TH2-biased CD4 T-cell response to vaccines. Toll-like receptor (TLR) agonists are currently being implemented as new vaccine adjuvants for TH1 activation, but their translation to the field of pediatric vaccines is facing the impairment of neonatal innate TLR responses.

Objective

We sought to analyze C-type lectin receptor pathways as an alternative or a coactivator to TLRs for neonatal dendritic cell activation for TH1 polarization.

Methods

Neonatal monocyte-derived dendritic cells (moDCs) were exposed to various combinations of TLR agonists with or without Dectin-1 agonist. IL-12 and IL-23 responses were analyzed at the transcriptional and protein levels after stimulation. The intracellular pathways triggered by combined TLR plus Dectin-1 stimulation was determined by using pharmacologic inhibitors. The capacity of neonatal moDCs to differentiate naive CD4 TH cells was evaluated in cocultures with heterologous neonatal naive T cells. Curdlan was finally tested as an adjuvant within a subunit tuberculosis vaccine in neonatal mice.

Results

Simultaneous coactivation through Dectin-1 and TLRs induced robust secretion of IL-12p70 by neonatal moDCs by unlocking transcriptional control on the p35 subunit of IL-12. Both the spleen tyrosine kinase and Raf-1 pathways were involved in this process, allowing differentiation of neonatal naive T cells toward IFN-γ–producing TH1 cells. In vivo a Dectin-1 agonist as adjuvant was sufficient to induce TH1 responses after vaccination of neonatal mice.

Conclusion

Coactivation of neonatal moDCs through Dectin-1 allows TLR-mediated IL-12p70 secretion and TH1 polarization of neonatal T cells. Dectin-1 agonists represent a promising TH1 adjuvant for pediatric vaccination.

El texto completo de este artículo está disponible en PDF.

Key words : Newborn, dendritic cells, TH1, adjuvant, C-type lectin receptor, Toll-like receptor, innate immunity

Abbreviations used : CARD9, CFU, CLR, Ct, DC, DZN, FACS, HBV, IFA, ITAM, mDC, moDC, MPLA, OVA, pDC, PIC, qPCR, Syk, TLR, WGP


Esquema


 Supported by an ANR grant (ANR 09-MIEN-017) and Fondation pour la Recherche Médicale (grant no. DEQ20120323719). This study also received funding from the French Government's Investissement d'Avenir program, Laboratoire d'Excellence “Integrative Biology of Emerging Infectious Diseases” (grant no. ANR-10-LABX-62-IBEID). S.L. was supported by ANR and the European Commission FP7 ADITEC program (HEALTH-F4-2011-280873). D.Z. was supported by DIM Malinf and Region Île de France.
 Disclosure of potential conflict of interest: P. Tissieres has received consultancy fees from Biomerieux and has received research support from the Merieux Foundation. R. Lo-Man has received research support from Fondation pour la recherche Medicale, the French National Agency for Research, the European Commmission, and Region Ile de France. The rest of the authors declare that they have no relevant conflicts of interest.


© 2015  American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 136 - N° 5

P. 1355 - novembre 2015 Regresar al número
Artículo precedente Artículo precedente
  • Respiratory syncytial virus infection of primary human mast cells induces the selective production of type I interferons, CXCL10, and CCL4
  • Ayham Al-Afif, Raidan Alyazidi, Sharon A. Oldford, Yan Y. Huang, Christine A. King, Nico Marr, Ian D. Haidl, Robert Anderson, Jean S. Marshall
| Artículo siguiente Artículo siguiente
  • Analysis of glutathione S-transferase allergen cross-reactivity in a North American population: Relevance for molecular diagnosis
  • Geoffrey A. Mueller, Lars C. Pedersen, Jill Glesner, Lori L. Edwards, Josefina Zakzuk, Robert E. London, L. Karla Arruda, Martin D. Chapman, Luis Caraballo, Anna Pomés

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.